Ellagic acid, sulforaphane, and ursolic acid in the prevention and therapy of breast cancer: current evidence and future perspectives

被引:52
作者
Jaman, Md. Sadikuj [1 ]
Abu Sayeed, Md. [2 ]
机构
[1] Rajshahi Univ, Dept Biochem & Mol Biol, Rajshahi 6205, Bangladesh
[2] Polytech Univ Marche, Dept Clin & Mol Sci, I-60126 Ancona, Italy
关键词
Breast cancer; Ellagic acid; Sulforaphane; Ursolic acid; In vitro; In vivo; ER-ALPHA; MAMMARY CARCINOGENESIS; SIGNALING PATHWAY; INDUCED APOPTOSIS; INHIBITS GROWTH; CELL-CYCLE; IN-VITRO; EXPRESSION; CHEMOPREVENTION; RECEPTOR;
D O I
10.1007/s12282-018-0866-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Globally, breast cancer is the most common cancer and the second leading cause of cancer-related death among women. Surgery, chemotherapy, hormonal therapy, and radiotherapy are currently available treatment options for breast cancer therapy. However, chemotherapy, hormonal therapy, and radiotherapy are often associated with side effects and multidrug resistance, recurrence, and lack of treatment in metastasis are the major problems in the treatment of breast cancer. Recently, dietary phytochemicals have emerged as advantageous agents for the prevention and therapy of cancer due to their safe nature. Ellagic acid (EA), sulforaphane (SF), and ursolic acid (UA), which are found in widely consumed fruits and vegetables, have been shown to inhibit breast cancer cell proliferation andto induce apoptosis. This review encompasses the role of EA, SF, and UA in the fight against breast cancer. Both in vitro and in vivo effects of these agents are presented.
引用
收藏
页码:517 / 528
页数:12
相关论文
共 50 条
[41]   Reversal of multidrug resistance in breast cancer cells by a combination of ursolic acid with doxorubicin [J].
Zong, Li ;
Cheng, Guorong ;
Liu, Shu ;
Pi, Zifeng ;
Liu, Zhiqiang ;
Song, Fengrui .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2019, 165 :268-275
[42]   Current Evidence and Future Perspectives on HuR and Breast Cancer Development, Prognosis, and Treatment [J].
Kotta-Loizou, Ioly ;
Vasilopoulos, Spyridon N. ;
Coutts, Robert H. A. ;
Theocharis, Stamatios .
NEOPLASIA, 2016, 18 (11) :674-688
[43]   Hypofractionated radiotherapy for breast cancer in elderly patients: current evidence and future perspectives [J].
del Campo, E. Rivin ;
Rivera, S. .
CANCER RADIOTHERAPIE, 2018, 22 (6-7) :635-639
[44]   Dietary Phenolics against Breast Cancer. A Critical Evidence-Based Review and Future Perspectives [J].
Angeles Avila-Galvez, Maria ;
Antonio Gimenez-Bastida, Juan ;
Carlos Espin, Juan ;
Gonzalez-Sarrias, Antonio .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (16) :1-33
[45]   Immunotherapy and immunobiomarker in breast cancer: current practice and future perspectives [J].
Liu, Kangsheng ;
Mao, Xiaodong ;
Li, Taiping ;
Xu, Zhirong ;
An, Ruifang .
AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (08) :3532-3547
[46]   Bevacizumab and breast cancer: current therapeutic progress and future perspectives [J].
Yang, Sherry X. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (12) :1715-1725
[47]   Evidence of the Beneficial Effects of Ursolic Acid against Lung Cancer [J].
Kornel, Amanda ;
Nadile, Matteo ;
Tsiani, Evangelia .
MOLECULES, 2022, 27 (21)
[48]   Triple-negative breast cancer therapy: Current and future perspectives (Review) [J].
Won, Kwang-Ai ;
Spruck, Charles .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2020, 57 (06) :1245-1261
[49]   Radiation therapy in breast cancer: a narrative review on current standards and future perspectives [J].
Kaidar-Person, Orit ;
Offersen, Birgitte, V .
ANNALS OF BREAST SURGERY, 2022, 6
[50]   Prevention of breast cancer: current state of the science and future opportunities [J].
Uray, Ivan P. ;
Brown, Powel H. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (12) :1583-1600